A multicenter study of 29 postmenopausal women diagnosed with prolactinomas during reproductive years (22 with microadenomas and 7 with macroadenomas) found that, after dopamine agonists suspension, 90% of the patients with microadenomas had remission of hyperprolactinemia and tumor reduction and 50% of them had no residual tumor, while in those with macroadenomas, prolactin levels increased slightly above the normal range (39). This evidence concerns the gene PRL and neoplasm.